Evidence map›Paper›PMID 40003620›Full record

ArticleLife (Basel, Switzerland)2025

Extracting Knowledge from Machine Learning Models to Diagnose Breast Cancer.

José Manuel Martínez-Ramírez, Cristobal Carmona, María Jesús Ramírez-Expósito, José Manuel Martínez-Martos

Abstract read
In one paragraph

Article in Life (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

José Manuel Martínez-RamírezDepartment of Computer Science, University of Jaén, E-23071 Jaén, Spain.ORCID 0009-0008-5949-8647
Cristobal CarmonaDepartment of Computer Science, University of Jaén, E-23071 Jaén, Spain.ORCID 0000-0001-7008-5378
María Jesús Ramírez-ExpósitoExperimental and Clinical Physiopathology Research Group CVI-1039, Department of Health Sciences, University of Jaén, E-23071 Jaén, Spain.ORCID 0000-0002-9379-203X
José Manuel Martínez-MartosExperimental and Clinical Physiopathology Research Group CVI-1039, Department of Health Sciences, University of Jaén, E-23071 Jaén, Spain.ORCID 0000-0002-2950-5614

Funding

Ministerio de Ciencia, Innovación y Universidades PID2023-149511OB-I00
6 · The paper itself

Abstract

This study explored the application of explainable machine learning models to enhance breast cancer diagnosis using serum biomarkers, contrary to many studies that focus on medical images and demographic data. The primary objective was to develop models that are not only accurate but also provide insights into the factors driving predictions, addressing the need for trustworthy AI in healthcare. Several classification models were evaluated, including OneR, JRIP, the FURIA, J48, the ADTree, and the Random Forest, all of which are known for their explainability. The dataset included a variety of biomarkers, such as electrolytes, metal ions, marker proteins, enzymes, lipid profiles, peptide hormones, steroid hormones, and hormone receptors. The Random Forest model achieved the highest accuracy at 99.401%, followed closely by JRIP, the FURIA, and the ADTree at 98.802%. OneR and J48 achieved 98.204% accuracy. Notably, the models identified oxytocin as a key predictive biomarker, with most models featuring it in their rules. Other significant parameters included GnRH, β-endorphin, vasopressin, IRAP, and APB, as well as factors like iron, cholinesterase, the total protein, progesterone, 5-nucleotidase, and the BMI, which are considered clinically relevant to breast cancer pathogenesis. This study discusses the roles of the identified parameters in cancer development, thus underscoring the potential of explainable machine learning models for enhancing early breast cancer diagnosis by focusing on explainability and the use of serum biomarkers.The combination of both can lead to improved early detection and personalized treatments, emphasizing the potential of these methods in clinical settings. The identified markers also provide additional research and therapeutic targets for breast cancer pathogenesis and a deep understanding of their interactions, advancing personalized approaches to breast cancer management.

Indexed as

breast cancerearly diagnosisexplainable AIIRAPoxytocinpeptide hormonesprogesteroneserum biomarkers

Identifiers

PMID40003620
PMCPMC11856414

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.